Identification

Name
Tolcapone
Accession Number
DB00323  (APRD00445)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. [Wikipedia]

Structure
Thumb
Synonyms
  • (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone
  • 3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone
  • 3,4-Dihydroxy-5-nitro-4'-methylbenzophenone
  • 4'-Methyl-3,4-dihydroxy-5-nitrobenzophenone
  • Tolcapon
  • Tolcapona
  • Tolcapone
  • Tolcaponum
External IDs
Ro 40-7592
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TasmarTablet100 mgOralHoffmann La Roche1997-10-201999-01-11Canada
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated200 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated200 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet200 mgOralHoffmann La Roche1997-10-201999-01-11Canada
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated200 mgOralMeda Ab1997-08-27Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TolcaponeTablet, film coated100 mg/1OralOceanside Pharmaceuticals2004-07-27Not applicableUs
TolcaponeTablet, coated100 mg/1OralPar Pharmaceutical2015-01-06Not applicableUs
International/Other Brands
Sen De Ning (Dexin Runsheng Pharmaceutical)
Categories
UNII
CIF6334OLY
CAS number
134308-13-7
Weight
Average: 273.2408
Monoisotopic: 273.063722467
Chemical Formula
C14H11NO5
InChI Key
MIQPIUSUKVNLNT-UHFFFAOYSA-N
InChI
InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
IUPAC Name
5-(4-methylbenzoyl)-3-nitrobenzene-1,2-diol
SMILES
CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O

Pharmacology

Indication

Used as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies.

Structured Indications
Pharmacodynamics

Tolcapone is a potent, selective, and reversible inhibitor of catechol-O-methyltransferase (COMT). In humans, COMT is distributed throughout various organs. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa catalyzing it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery. When tolcapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that these sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease in patients as well as increased levodopa adverse effects, sometimes requiring a decrease in the dose of levodopa.

Mechanism of action

The precise mechanism of action of tolcapone is unknown, but it is believed to be related to its ability to inhibit COMT and alter the plasma pharmacokinetics of levodopa, resulting in an increase in plasma levodopa concentrations. The inhibition of COMT also causes a reduction in circulating 3-OMD as a result of decreased peripheral metabolism of levodopa. This may lead to an increase distribution of levodopa into the CNS through the reduction of its competitive substrate, 3-OMD, for transport mechanisms. Sustained levodopa concentrations presumably result in more consistent dopaminergic stimulation, resulting in greater reduction in the manifestations of parkinsonian syndrome.

TargetActionsOrganism
ACatechol O-methyltransferase
inhibitor
Human
Absorption

Rapidly absorbed (absolute bioavailability is about 65%)

Volume of distribution
  • 9 L
Protein binding

> 99.9% (to serum albumin)

Metabolism

The main metabolic pathway of tolcapone is glucuronidation

Route of elimination

Tolcapone is almost completely metabolized prior to excretion, with only a very small amount (0.5% of dose) found unchanged in urine. The glucuronide conjugate of tolcapone is mainly excreted in the urine but is also excreted in the bile.

Half life

2-3.5 hours

Clearance
  • 7 L/h
Toxicity

LD50 = 1600 mg/kg (Orally in rats)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Tolcapone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Acebutolol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Tolcapone is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tolcapone.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Tolcapone is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tolcapone.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Tolcapone.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Tolcapone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tolcapone.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Tolcapone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amphetamine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolcapone.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Tolcapone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Tolcapone.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tolcapone.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tolcapone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tolcapone.Approved
AtenololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Azaperone.Investigational, Vet Approved
AzelastineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Azilsartan medoxomil.Approved, Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tolcapone.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Tolcapone.Experimental
BarbitalBarbital may increase the hypotensive activities of Tolcapone.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Tolcapone.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Tolcapone.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Betaxolol.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Tolcapone.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Tolcapone is combined with Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tolcapone.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Tolcapone is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tolcapone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tolcapone.Approved, Investigational
BuprenorphineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tolcapone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tolcapone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tolcapone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Tolcapone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Tolcapone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tolcapone.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Tolcapone is combined with Canertinib.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tolcapone.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tolcapone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Caroxazone.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carvedilol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tolcapone.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tolcapone.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorzoxazone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tolcapone.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Tolcapone is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Tolcapone.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Tolcapone.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tolcapone.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tolcapone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tolcapone.Approved
CocaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tolcapone.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tolcapone.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Tolcapone.Approved
CyclizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tolcapone.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dantrolene.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tolcapone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tolcapone.Approved, Illicit, Investigational, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Diclofenamide.Approved, Investigational
Diethyl etherThe risk or severity of adverse effects can be increased when Tolcapone is combined with Diethyl ether.Experimental
DiethylstilbestrolThe metabolism of Diethylstilbestrol can be decreased when combined with Tolcapone.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tolcapone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Tolcapone is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tolcapone.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tolcapone.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dixyrazine.Experimental
DobutamineThe metabolism of Dobutamine can be decreased when combined with Tolcapone.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Tolcapone.Approved
DoramectinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Doxepin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Tolcapone is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Drotebanol.Experimental, Illicit
DuloxetineTolcapone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Tolcapone is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Tolcapone.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolcapone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Tolcapone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Tolcapone is combined with Eprosartan.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Tolcapone is combined with Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tolcapone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tolcapone.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etacrynic acid.Approved, Investigational
EthanolTolcapone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tolcapone.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tolcapone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fexofenadine.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tolcapone.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tolcapone.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tolcapone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tolcapone.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tolcapone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tolcapone.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tolcapone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tolcapone.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Tolcapone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Hydracarbazine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneTolcapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Tolcapone.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolcapone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Tolcapone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolcapone.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tolcapone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Tolcapone is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Tolcapone.Withdrawn
IproclozideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iproniazid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Tolcapone is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tolcapone.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isradipine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tolcapone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ketobemidone.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Labetalol.Approved
LacidipineTolcapone may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Tolcapone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tolcapone.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levocetirizine.Approved
LevodopaTolcapone may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tolcapone.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Tolcapone.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Tolcapone.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tolcapone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lormetazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Tolcapone is combined with Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tolcapone.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tolcapone.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Tolcapone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Maprotiline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Tolcapone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tolcapone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tolcapone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalMethohexital may increase the hypotensive activities of Tolcapone.Approved
MethotrimeprazineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methyclothiazide.Approved
MethyldopaThe metabolism of Methyldopa can be decreased when combined with Tolcapone.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methylecgonine.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methylene blue.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Tolcapone.Approved
MetipranololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metoprolol.Approved, Investigational
MetyrosineTolcapone may increase the sedative activities of Metyrosine.Approved
MicafunginThe metabolism of Micafungin can be decreased when combined with Tolcapone.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tolcapone.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Tolcapone is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Minoxidil.Approved, Investigational
MirtazapineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Moclobemide.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tolcapone.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Tolcapone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tolcapone.Approved
NebivololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nesiritide.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nialamide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Tolcapone.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Tolcapone.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tolcapone.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tolcapone.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tolcapone.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Tolcapone.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tolcapone.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tolcapone.Approved, Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tolcapone.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Tolcapone is combined with Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Tolcapone is combined with Opium.Approved, Illicit
OrphenadrineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Tolcapone is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tolcapone.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tolcapone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tolcapone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tolcapone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tolcapone.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tolcapone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Papaverine.Approved, Investigational
ParaldehydeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tolcapone.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Tolcapone.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved
PerazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Perazine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tolcapone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tolcapone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Tolcapone.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tolcapone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenoxypropazine.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Tolcapone.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tolcapone.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tolcapone.Approved
PindololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pindolol.Approved, Investigational
PipamperoneThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Tolcapone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Piritramide.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pomalidomide.Approved
PramipexoleTolcapone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Prazosin.Approved
PregabalinThe therapeutic efficacy of Tolcapone can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Prilocaine.Approved
PrimidonePrimidone may increase the hypotensive activities of Tolcapone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tolcapone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tolcapone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Tolcapone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tolcapone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Tolcapone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Tolcapone is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tolcapone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Quinapril.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolcapone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Reserpine.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Tolcapone is combined with Riociguat.Approved
RisperidoneTolcapone may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Romifidine.Vet Approved
RopiniroleTolcapone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolcapone.Approved
RotigotineTolcapone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tolcapone.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tolcapone.Approved
SafrazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Scopolamine.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Tolcapone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tolcapone.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved
SotalolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Tolcapone.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolcapone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sultopride.Experimental
SuvorexantTolcapone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Tolcapone.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tasimelteon.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Tolcapone is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tolcapone.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Terazosin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tetrodotoxin.Investigational
ThalidomideTolcapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Tolcapone.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Tolcapone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tolcapone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tolcapone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Tolcapone is combined with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tizanidine.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Tolcapone.Approved, Vet Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tolcapone.Approved
TorasemideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tolcapone.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tolcapone.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tolcapone.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Tolcapone is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Tolcapone is combined with Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Tolcapone is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Tolcapone is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Tolcapone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tolcapone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tolcapone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zolazepam.Vet Approved
ZolpidemTolcapone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tolcapone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tolcapone.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Guay DR: Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy. 1999 Jan;19(1):6-20. [PubMed:9917075]
  2. Keating GM, Lyseng-Williamson KA: Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs. 2005;19(2):165-84. [PubMed:15697329]
  3. Truong DD: Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14. [PubMed:19503773]
  4. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800]
  5. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160]
External Links
Human Metabolome Database
HMDB0014468
KEGG Drug
D00786
KEGG Compound
C07949
PubChem Compound
4659569
PubChem Substance
46504932
ChemSpider
3848682
BindingDB
50108877
ChEBI
63630
ChEMBL
CHEMBL1324
Therapeutic Targets Database
DAP000607
PharmGKB
PA451720
HET
TCW
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Tolcapone
ATC Codes
N04BX01 — Tolcapone
PDB Entries
3s68 / 4d7b / 4pyl / 5a6i
FDA label
Download (71.3 KB)
MSDS
Download (17.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
1RecruitingTreatmentMedulloblastomas / Neuroblastomas1
1Unknown StatusTreatmentCocaine-Related Disorders1
2Active Not RecruitingTreatmentFrontotemporal Lobar Degeneration1
2CompletedNot AvailableSchizophrenic Disorders1
2CompletedTreatmentNicotine Dependence1
2CompletedTreatmentPathological Gambling1
2CompletedTreatmentTobacco Use Disorders1
2Enrolling by InvitationTreatmentBrain Injuries,Traumatic / Brain Injury / Mild Cognitive Impairment (MCI) / Neurocognitive Disorders1
2RecruitingTreatmentAlcohol Use Disorder (AUD)1
2, 3RecruitingTreatmentObsessive-Compulsive Disorder (OCD)1
4CompletedTreatmentParkinson's Disease (PD)1
Not AvailableActive Not RecruitingBasic ScienceAddictions1
Not AvailableActive Not RecruitingBasic ScienceImpulsive Behaviors1
Not AvailableCompletedBasic SciencePathological Gambling1
Not AvailableRecruitingNot AvailableAtypical Parkinson Disease / Corticobasal Degeneration / Gait, Frontal / Multiple System Atrophy (MSA) / Parkinson's Disease (PD) / Parkinsonian Disorders / Progressive Supranuclear Palsy (PSP)1
Not AvailableRecruitingBasic ScienceAlcohol Abuse / Impulsive Behaviors1
Not AvailableRecruitingBasic ScienceMild Traumatic Brain Injury (MTBI)1
Not AvailableRecruitingTreatmentNicotine Dependence1

Pharmacoeconomics

Manufacturers
  • Valeant pharmaceuticals international
Packagers
  • Legacy Pharmaceuticals Packaging LLC
  • Murfreesboro Pharmaceutical Nursing Supply
  • Valeant Ltd.
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral200 mg
Tablet, film coatedOral100 mg
Tablet, film coatedOral200 mg
Tablet, coatedOral100 mg/1
Tablet, film coatedOral100 mg/1
Prices
Unit descriptionCostUnit
Tasmar 100 mg tablet8.13USD tablet
Tasmar 200 mg tablet7.44USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5476875No1992-12-192012-12-19Us
US5236952No1995-01-292012-01-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0569 mg/mLALOGPS
logP2.63ALOGPS
logP3.28ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)5.17ChemAxon
pKa (Strongest Basic)-6.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area103.35 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity72.96 m3·mol-1ChemAxon
Polarizability26.44 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9041
Blood Brain Barrier-0.9418
Caco-2 permeable-0.5422
P-glycoprotein substrateNon-substrate0.6612
P-glycoprotein inhibitor INon-inhibitor0.6371
P-glycoprotein inhibitor IINon-inhibitor0.9128
Renal organic cation transporterNon-inhibitor0.933
CYP450 2C9 substrateNon-substrate0.6554
CYP450 2D6 substrateNon-substrate0.894
CYP450 3A4 substrateSubstrate0.5245
CYP450 1A2 substrateNon-inhibitor0.9199
CYP450 2C9 inhibitorInhibitor0.8317
CYP450 2D6 inhibitorNon-inhibitor0.9135
CYP450 2C19 inhibitorNon-inhibitor0.8762
CYP450 3A4 inhibitorNon-inhibitor0.6585
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5984
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6079
BiodegradationNot ready biodegradable0.9433
Rat acute toxicity2.2574 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8346
hERG inhibition (predictor II)Non-inhibitor0.8311
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00e9-0980000000-495401c19ad2c2091c1a

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzophenones
Direct Parent
Benzophenones
Alternative Parents
Aryl-phenylketones / Diphenylmethanes / Nitrophenols / Nitrobenzenes / Benzoyl derivatives / Catechols / Nitroaromatic compounds / Toluenes / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids
show 6 more
Substituents
Benzophenone / Diphenylmethane / Aryl-phenylketone / Nitrophenol / Nitrobenzene / Nitroaromatic compound / Benzoyl / Catechol / Aryl ketone / 1-hydroxy-4-unsubstituted benzenoid
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
benzophenones (CHEBI:63630) / a small molecule (CPD-7664)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
O-methyltransferase activity
Specific Function
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOP...
Gene Name
COMT
Uniprot ID
P21964
Uniprot Name
Catechol O-methyltransferase
Molecular Weight
30036.77 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Ries V, Selzer R, Eichhorn T, Oertel WH, Eggert K: Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Clin Neuropharmacol. 2010 May;33(3):142-50. doi: 10.1097/WNF.0b013e3181d99d6f. [PubMed:20502133]
  3. Guay DR: Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy. 1999 Jan;19(1):6-20. [PubMed:9917075]
  4. Keating GM, Lyseng-Williamson KA: Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs. 2005;19(2):165-84. [PubMed:15697329]
  5. Truong DD: Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14. [PubMed:19503773]
  6. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR: Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007 May;32(5):1011-20. Epub 2006 Oct 25. [PubMed:17063156]
  7. Stocchi F, De Pandis MF: Utility of tolcapone in fluctuating Parkinson's disease. Clin Interv Aging. 2006;1(4):317-25. [PubMed:18046910]
  8. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800]
  9. Tai CH, Wu RM: Catechol-O-methyltransferase and Parkinson's disease. Acta Med Okayama. 2002 Feb;56(1):1-6. [PubMed:11873938]
  10. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160]
  11. Ruottinen HM, Rinne UK: COMT inhibition in the treatment of Parkinson's disease. J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. [PubMed:9808337]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 01:56